Twenty-four-Month Outcomes of Excimer Laser Trabeculostomy in Patients With OAG Undergoing Cataract Surgery
CLOSE
MENU

Twenty-four-Month Outcomes of Excimer Laser Trabeculostomy in Patients With OAG Undergoing Cataract Surgery


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Twenty-four-Month Outcomes of Excimer Laser Trabeculostomy in Patients With OAG Undergoing Cataract Surgery


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Summary

Purpose: To assess the 24-mo outcomes of the excimer laser in reducing intraocular pressure (IOP) in patients (pts) with mild-to-moderate primary open-angle glaucoma (POAG) undergoing cataract surgery.

Methods: Prospective, non-randomized, US trial at 20 sites (NCT04899063). Pts were treated with Elios procedure (B+L). Co-primary effectiveness endpoints were ≥20% reduction in unmedicated diurnal IOP and mean change in DIOP at Month 24. Safety was also assessed.

Results: A total of 318 pts underwent the procedure (mean age 70 years). At 24-mo, 76.1% of patients achieved a ≥20% decrease in unmedicated IOP, mean IOP change was −7.35 mmHg and mean±SD meds decreased from 1.5±0.7 to 0.3±0.8. Most ocular AEs were mild to moderate and occurred within Month 1. Endothelial cell density stabilized by Month 3, similar to phaco alone, and visual field parameters remained stable.

Conclusions: Both co-primary effectiveness endpoints were met, demonstrating sustained and clinically meaningful reductions in unmedicated diurnal IOP, decreased medication burden, and a favorable safety profile.

For More Information:

Get Support

Contact Us

Contact a
Representative

Find My Local Rep link-out icon

Submit a
Medical Inquiry

Complete the Form